Objective: The report of the 'Mississippi baby' who was initiated on antiretroviral therapy (ART) within 30 h of birth and maintained viral suppression off ART for 27 months has increased interest in the timing of ART initiation early in life. We examined associations between age at ART initiation and virologic outcomes in five cohorts of HIV-infected infants and young children who initiated ART before 2 years of age in Johannesburg, South Africa.
Introduction
Evidence from the children with HIV early antiretroviral therapy randomized clinical trial in South Africa and other observational studies indicates that initiation of antiretroviral therapy (ART) early in life reduces morbidity and mortality in HIV-infected infants [1] [2] [3] [4] [5] . These findings have informed treatment guidelines which now advise initiation of ART irrespective of clinical and immunological status in all HIV-infected infants and children [6] [7] [8] . The report of the 'Mississippi baby' who was initiated on ART within 30 h of birth and who maintained viral suppression off therapy for 27 months [9] has further stimulated interest in the possible benefits of initiating ART soon after birth.
Data on the effects of the timing of early ART initiation on virologic outcomes, including initial virologic response and sustained virologic control after suppression are limited. Some studies have reported better initial virologic response in children started on ART less than 3-6 months of age compared with children started after 6 months of age [4, 10] whereas others have reported no differences in short-term suppression rates [11, 12] . Reports of infants started on ART in the first months of life with no comparator group of children started at older ages have shown varied rates of initial suppression [13] [14] [15] [16] . Few studies have compared later virologic control, that is, maintenance of suppression without rebound after achieving initial suppression, between children initiating ART at earlier versus later ages. One study of children who initiated ART younger or older than 1 year of age and who achieved virologic suppression found no association between age at ART start and rebound of HIV RNA more than 400 copies/ml at later ages [17] .
With increasing attention to the possible benefits of ART initiation in newborns, it is important to investigate the effects of the timing of ART initiation on virologic response in larger cohorts in sub-Saharan Africa where the vast majority of new pediatric infections occur [18] . Here, using data from five study cohorts of HIV-infected children initiating ART before 2 years of age in Johannesburg, South Africa, we examine the association between age at starting ART and initial viral response in three cohorts and later virologic control after achieving suppression in two cohorts.
Methods

Study populations
Five cohorts of HIV-infected infants and young children in Johannesburg, South Africa were included in this analysis (Table 1) . Three cohorts of children initiating ART (cohorts A, B, and C.1) were suitable to examine the association between age at ART initiation and initial response to treatment. Two cohorts of children who had achieved virologic suppression after ART initiation (cohorts C.2 and D) were suitable to assess the association between age at ART initiation and later virologic control.
Cohort A included newly diagnosed, treatment-naïve HIV-infected infants and young children identified at hospital admissions, prevention of mother-to-child transmission (PMTCT) follow-up visits, and immunization services as part of an active surveillance study intended to improve engagement in care and ART initiation at three hospitals and two affiliated clinics conducted between January 2011 and December 2011 [19] [20] [21] . We restricted the analysis to 219 children known to have been initiated on ART before 2 years of age. At enrollment into the surveillance study (pretreatment), blood samples were collected from each child for plasma HIV RNA tests (AmpliPrep/COBAS TaqMan HIV Test, version 2.0; Roche, Branchburg, New Jersey, USA) and CD4 þ percentage. Sociodemographic and clinical information was also collected. Subsequent information on survival, HIV RNA, and CD4 þ percentage, as close as possible to 6 months post-ART initiation, was abstracted from medical records.
Cohort B included 718 newly diagnosed, treatmentnaïve infants, and young children who initiated ART before 2 years of age as part of public HIV services at the Empilweni Services and Research Unit at Rahima Moosa Mother and Child Hospital (RMMCH) between January 2004 and July 2012 and who had at least one follow-up visit after ART initiation or died after ART initiation. At this time ritonavir-boosted lopinavir (LPV/r) based was given to children in this age group and viral load testing was recommended every 6 months after ART initiation [22] . Demographic information, age at ART initiation, HIV RNA, and CD4 þ percentage were extracted from a routine database maintained by the site for clinical care purposes.
Cohort C.1 consisted of 323 newly diagnosed, treatmentnaïve infants, and young children enrolled into the prerandomization phase of an ART strategies trial that took place at RMMCH from April 2005 to June 2010 [23] . All children had been exposed to nevirapine used for PMTCT given to the mother, to the child, or both and were initiated on LPV/r-based ART before 2 years of age. Blood samples for plasma HIV RNA quantification (Roche Amplicor HIV test, version 1.5, Roche) and CD4 þ percentages were measured before treatment began and at 4, 12, 24, 36, and 52 weeks after treatment initiation as part of the prerandomization phase.
Cohort C.2 includes all 195 of the children from Cohort C.1 who met criteria for randomization (HIV RNA < 400 copies/ml for at least 3 months within the first 12 months of treatment) and were assigned to remain on LPV/r (N ¼ 99) or switch to nevirapine (N ¼ 96) (ClinicalTrials.gov: NCT00117728) [24, 25] . Children undergoing randomization after viral suppression had been achieved (a median of 9 months after ART initiation) had additional blood samples collected at scheduled postrandomization visits (4, 16, 24, 36 , and 52 weeks).
Cohort D included children 3-5 years of age with a history of nevirapine exposure for PMTCT who were suppressed on LPV/r (HIV RNA < 50 copies/ml at the time of enrollment into the study) and randomized to either remain on LPV/r or switch to efavirenz as part of an ART strategies trial that took place at RMMCH from June 2010 to December 2013 (ClinicalTrials.gov: NCT01146873) [26] . This analysis was limited to 293 children who initiated ART before 2 years of age, including 145 children randomized to remain on LPV/r and 148 randomized to switch to efavirenz. Plasma HIV RNA (AmpliPrep/COBAS TaqMan HIV Test, version 2.0, Roche) measurements were obtained at randomization and scheduled postrandomization visits (4, 8, 16, 24 , and 48 weeks). CD4 þ percentage was measured at study entry and 24 and 48 weeks postrandomization.
Studies were approved by the Institutional Review Boards of Columbia University (New York City, New York, USA) and the University of the Witwatersrand (Johannesburg, South Africa). Signed informed consent for all procedures and data was provided by each child's guardian for cohorts A, C.1, C.2, and D and for data sharing for Cohort B.
Statistical analysis
To examine effects of the timing of ART initiation, we compared children who initiated ART less than 6 months of age to those who started ART 6-24 months of age. The less than 6 months age category was refined further in some analyses. Two primary virologic outcomes were examined: initial response to ART and later sustained virologic control after achieving suppression on ART.
Initial response to ART was examined in cohorts A, B, and C.1. HIV RNA (categorized as < 50, 50-1000, !1000 copies/ml) measured around 6 months post-ART initiation was compared between age at ART initiation groups. We defined the window for '6 months' to be between 3 and 12 months. If more than one result was available, the result nearest to 6 months was chosen. Secondary outcomes for cohorts A, B, and C.1 included CD4 þ percentage as a continuous and as a categorical variable (<10, 10-15, and !15) at 6 months post-ART initiation. Vital status by 6 months post-ART initiation was also determined.
Later virologic control after suppression on ART was assessed in cohorts C.2 and D. The proportion of children in three HIV RNA categories (<50, 50-1000, !1000 copies/ml) at scheduled visits postrandomization was compared between age at ART initiation groups. A generalized estimating equation (GEE) model with an unstructured correlation structure was used to examine the overall effect of age at ART initiation on HIV RNA outcomes at repeated visits. Other correlation structures produced similar results. We adjusted for treatment randomization group (LPV/r vs. nevirapine in Cohort C.2; LPV/r vs. efavirenz in Cohort D).
Additionally, we compared area under the plasma viral load curve (AUVLC), a measure of 'cumulative viral load,' between age at ART initiation groups. The AUVLC in log10 copy weeks/ml at scheduled visits in the two Children from cohort C.1 who met criteria for randomization (plasma HIV RNA < 400 copies/ml for at least 3 months within the first 12 months of treatment) and were assigned to remain on LPV/r or switch to nevirapine as part of an ART strategies trial (ClinicalTrials.gov: NCT00117728)
Later virologic control Cohort D [26] 293 2010-2013 Children 3-5 years of age who were suppressed on LPV/r (plasma HIV RNA < 50 copies/ml at the time of enrollment into the study) and randomized to remain on LPV/r or switch to efavirenz as part of an ART strategies trial (ClinicalTrials.gov: NCT01146873)
Later virologic control ART, antiretroviral therapy.
cohorts was calculated using the trapezoidal rule, whereby larger areas indicate higher cumulative viremia [27] . The data were normalized so that a child with an AUCVL of 0 was considered fully suppressed and a child with a detectable AUCVL was not fully suppressed at followup visits.
Statistical comparisons were conducted using x-squared or Fisher's exact tests for categorical variables, analysis of variance and t-tests for normally-distributed continuous variables, and Kruskal-Wallis tests for nonnormally distributed continuous variables. All P values are twotailed and P values less than 0.05 were considered statistically significant. Analyses were performed using SAS version 9.4 (SAS Institute Inc., Cary, North Carolina, USA).
Results
Characteristics
Characteristics of the children included in this study are shown in Table 2 Initial response to treatment Pretreatment, a higher proportion of children starting ART early (<6 months) had higher HIV RNA levels (!750 000 copies/ml) than children starting ART late (6-24 months of age) in all three cohorts (Table 3) . Pretreatment CD4 þ percentage was consistently higher in the early initiators and the proportion of children underweight (WAZ < À2) was lower in children starting ART early compared with late in Cohort A only (Table  3) .
Posttreatment, it was only in Cohort A that children who initiated ART early were more likely to be suppressed (<50 copies/ml) at 6 months than children who initiated ART late. This was not observed in cohorts B and C.1 (Table 3) . In a finer stratification of age at ART initiation in cohort A, the proportions of children suppressed less ART, antiretroviral therapy; ATZ/r, ritonavir-boosted atazanavir; LPV/r, ritonavir-boosted lopinavir; PMTCT, prevention of mother-to-child transmission of HIV; WAZ, weight-for-age z-score.
than 50 copies/ml 6 months post-ART initiation were 35.5, 25.9, and 9.8% in those who started ART less than 3 months, 3-6 months, and 6-24 months, respectively. This trend was not seen in cohorts B and C.1. Adjustment for pretreatment viral load or other pretreatment characteristics including sex, CD4 þ percentage, and WAZ did not change these results (data not shown). When the three cohorts were combined, there was no difference in suppression to less than 50 copies by 6 months for children who initiated ART early (<6 months) vs. late (6-24 months), even after adjustment for pretreatment HIV RNA and CD4 R percentage, and weight-for-age Z-score preantiretroviral therapy initiation, and plasma HIV-1 RNA quantity, CD4
R percentage, and vital status 6 months post-ART initiation in cohorts A, B, and C.1 stratified by age at antiretroviral therapy initiation (<6 months vs. 6-24 months).
Cohort A age at ART initiation (months)
Cohort B age at ART initiation (months) Cohort C.1 age at ART initiation (months) <6 6 -2 4 P <6 Note: Assay to assess HIV-RNA quantity in Cohort C.1 used an upper limit of detection of 750 000 copies/ml, which led to truncation of more than half of the measurements.
In cohorts A, B, and C.1 the mean CD4 þ percentage at 6 months post-ART initiation was higher in children who initiated ARTearly (Table 3) but after adjustment for  pretreatment CD4 þ percentage in all three cohorts, the difference was no longer statistically significant (P ¼ 0.087, 0.403, 0.201). There was a trend toward lower mortality among children treated less than 6 months vs treated 6-24 months in Cohort A (P ¼ 0.076) ( Table 3 ). In a further stratification of age at ART initiation categories into less than 3 months, 3-6 months, and 6-24 months, the proportions of children who died by 6 months post-ART initiation were 4.6, 16.4, and 20.2%, respectively, in Cohort A (P ¼ 0.006). No differences between age at ART initiation groups in the proportion of deaths was observed in cohorts B and C.1.
We combined the data from the three cohorts to investigate effects of the timing of ART initiation in monthly increments in the first 6 months of life. No clear trends in the proportion of children suppressed by 6 months post-ART initiation were observed by age at ART initiation in months. The percentage of children suppressed less than 50 copies/ml ranged from 25 to 49.3% across all age intervals in months of age at ART initiation (Table S1 , http://links.lww.com/QAD/B6).
Later virologic control
Age at ART start influenced later virologic control after viral suppression in both cohorts C.2 and D. Of 195 children in Cohort C.2, children less than 6 months at ART start were less likely to have a plasma HIV RNA 50-1000 copies/ml and plasma HIV RNA more than 1000 copies at all scheduled postrandomization visits than children 6-24 months at ART start (Fig. 1) . In a GEE model accounting for repeated visits, the odds of having an HIV RNA 50-1000 vs. less than 50 copies/ml was lower in children who initiated ARTearly compared with children who initiated ART late, adjusted for randomization group (OR ¼ 0.34, 95% CI: 0.19, 0.61). A similar trend was seen in the GEE model for having an HIV RNA less than 1000 vs. less than 1000 copies/ml (OR ¼ 0.29, 95% CI: 0.08, 1.11).
Of 293 children in Cohort D, children less than 6 months at ART start were less likely to have a plasma HIV RNA 50-1000 copies/ml at all but one scheduled postrandomization visit than children 6-24 months at ART start. There were no consistent differences in the proportion of children with HIV RNA more than 1000 copies/ml by age at starting ART but HIV RNA more than 1000 copies/ml was rare in both groups (Fig. 1) . In a GEE model, the odds of having an HIV RNA 50-1000 copies/ml vs. less than 50 copies/ml for children who initiated ART early was 0.46 times that of children who initiated ART late, adjusted for randomization group (OR ¼ 0.46, 95% CI: 0.24, 0.87).
In Cohort C.2, a smaller proportion of the children who started treatment early had a detectable AUVLC compared with children who started treatment late (30.0 vs. 50.7%, P ¼ 0.012) across all scheduled trial visits. Among those with a detectable AUVLC, children starting treatment early had a lower median log 10 copy weeks/ml than children starting treatment late (1.7 vs. 9.5, P ¼ 0.03). Similarly, in Cohort D, a smaller proportion of the children who started treatment early had a detectable AUVLC compared with children who started treatment late (19.1 vs. 31.9%, P ¼ 0.013) across all scheduled trial visits. Among those with a detectable AUVLC, there was no difference in median log 10 copy years/ml between children starting ART early and late (Fig. 2) .
Discussion
We did not observe a consistent benefit of early ART initiation on rates of initial viral suppression in the first 6 months of treatment in three nonoverlapping cohorts from Johannesburg, South Africa. In one of the three cohorts, we observed better virological suppression by 6 months in children who initiated ART compared with those who initiated 6-24 months but no differences were observed in the other two. Pretreatment viral loads and CD4 þ percentages in all three cohorts were higher in children younger at ART initiation, consistent with the natural history of HIV infection in infancy [28] [29] [30] [31] . However, even after accounting for these differences, in a combined analysis of the three cohorts, there were no significant differences in initial viral suppression between children starting treatment early and late. The higher pretreatment viral loads suggest that the rate of decline was more rapid in the early-treated groups but truncation in the upper range of the assays in use at the time limited our capacity to measure this directly.
Although the better virologic response in children initiating ART early observed in Cohort A is encouraging, the lack of confirmation in the other two cohorts leads us to suspect that other factors may be involved. Cohort A was a surveillance study which was intended to actively identify mothers and infants not already engaged in care. These children were predominantly identified through hospital admissions and, in particular, more children starting ART early (<6 months) were identified through routine PMTCT services. Hence these children may have had less advanced disease and benefit most from early treatment than children in the other cohorts starting treatment early. There was some evidence to suggest this speculation may be valid, as pretreatment weight-for-age z-scores, a sensitive marker of disease progression, were slightly better in children starting treatment early in Cohort A compared with the other two cohorts. Better surveillance systems in place to identify HIV-infected infants to initiate ART at an early age may improve initial outcomes. A prior study has also reported higher rates of viral suppression less than 500 copies/ml by 6 months in those starting ART 3 months or less of age compared with those starting treatment 3-12 months of age (63 vs. 19%, P < 0.001) [10] . Another study reported more early treated infants (<6 months of age) reaching undetectable viral load than later treated infants (6-52 months of age) over a median follow-up time of 4.1 years (73.3 vs. 30.1%, P < 0.0001) [4] . Two other studies reported no differences in initial virologic suppression at 6 months between children starting early and late [11, 12] .
Of note, overall rates of initial viral suppression at 6 months were low. Only 31, 40.1, and 26.5% of earlytreated infants in cohorts A, B, and C.1, respectively, were suppressed less than 50 copies/ml at 6 months after starting ART. The large proportion of infants at risk for viral failure is concerning, particularly as options for second-line regimens are limited for children.
In children who had initially achieved suppression, we observed a consistent benefit of early ART initiation on rates of sustained viral suppression in the two cohorts we examined. Compared with children who started treatment later in infancy and early childhood (6-24 months of age), children who started treatment early (<6 months) were less likely to experience viral rebound and had a lower cumulative viral load in followup than children who started treatment later. This benefit was observed in both cohorts and across the different treatment regimens (nevirapine, efavirenz, and LPV/r) that were evaluated in these two trials. Although age at ART initiation (<1 year vs. > 1 year) in older children who achieved virologic suppression was not associated with rebound of HIV RNA less than 400 copies/ml in one study [17] , other studies have reported better long-term virologic control in infants starting ART at an early age. In a group of 20 children from the children with HIVearly antiretroviral therapy randomized clinical trial maintained on suppressive ART for 7-8 years, nine of 12 (75%) children starting ART before 2 months of age had undetectable plasma HIV RNA compared with three of eight (37.5%) infants who started after 2 months of age (P ¼ 0.17) [32] . A study of HIV-infected children maintained on ART for up to 18 years and virally suppressed on conventional assays found plasma viremia by ultrasensitive assays to be below the limit of detection (<2 copies/ml) in all four children who initiated ART early (before 3 months of age) but detectable (median 8 copies/ml) in all four children who did not initiate ART until later childhood (6-15 years) [33] .
HIV infection requires life-long ART because of its persistence in latent viral reservoirs located in long-lived resting memory CD4 þ T cells and other anatomic sanctuaries that harbor dormant replication-competent proviruses [34, 35] . ART targets replicating virus and has not been shown to eradicate these replication-competent HIV reservoirs. The establishment of the latent viral reservoir occurs early during primary infection [36] , and evidence in adults supports that early initiation of ART close to the time of HIV acquisition may limit HIV reservoir size [37] [38] [39] and lead to HIV remission in certain adults, termed posttreatment controllers [40, 41] . In infants, several reports have indicated that early ART initiation limits the size of the viral reservoir [13, 32, 33, 42] . A study of 17 HIV-infected infants starting treatment in the first 6 months of life found a significantly smaller viral reservoir in infants treated before 6 weeks of age compared with children initiating ART between 6 weeks and 6 months of age [13] . in this study, and increasing the possibility for sustained suppression with potent ART.
Our study had limitations. Our analysis used a 6 month cut off for early ART initiation, but even earlier age intervals are important to investigate. In all of our cohorts, there were only small numbers of children initiating ART before 6 weeks of age, too few for a subgroup analysis. In addition, although we combined data from three cohorts in our evaluation of initial response to treatment, we were unable to account for differences in viral load assays as well as changes in drug regimens, dosing, and clinical practice taking place in the time period during which children were enrolled.
In conclusion, our study demonstrates improved virologic control after initial viral suppression in children starting ART before 6 months of age compared with those starting at 6-24 months in two large cohorts. We did not find consistent benefits of early treatment on initial viral suppression. Our results suggest that there are virological benefits of early treatment in addition to those shown for reduction of mortality and morbidity [1, 2] , growth [43] , and neurological outcomes [44] . These results provide additional impetus for early initiation of ART in HIVinfected infants.
